Protagenic Therapeutics, Inc.new (PTIX): Nasdaq/NYSE listing notice — Protagenic Therapeutics receives Nasdaq minimum bid price deficiency notice

Protagenic Therapeutics, Inc.new

Nasdaq notified PTIX on Nov 21, 2023 that common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
Company has 180 calendar days, until May 19, 2024, to regain compliance with bid price requirement.
To regain compliance, closing bid price must be at least $1.00 for ten consecutive business days.
If not cured by May 19, 2024, PTIX may be eligible for an additional 180-day period if it meets other listing standards.
Stock continues trading on Nasdaq Capital Market under symbol PTIX; no immediate delisting effect.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 21, 2023, Protagenic Therapeutics, Inc. (“the Company”) received a deficiency letter (the “Notification Letter”) from the Nasdaq Listing Qualifications (“Nasdaq”) stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001493152-23-043098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.